Table of Contents
ISRN Urology
Volume 2014, Article ID 140654, 8 pages
http://dx.doi.org/10.1155/2014/140654
Clinical Study

Alpha 1-Adrenoceptor Blocker May Improve Not Only Voiding But Also Storage Lower Urinary Tract Symptoms Caused by 125I Brachytherapy for Prostate Cancer

1Department of Urology, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Fukui 910-1193, Japan
2Department of Radiology, Faculty of Medical Sciences, University of Fukui, Fukui 910-1193, Japan

Received 5 January 2014; Accepted 2 March 2014; Published 30 March 2014

Academic Editors: A. M. El-Assmy, A. Natali, A. K. Singla, and K. H. Tsui

Copyright © 2014 Nobuyuki Oyama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2012,” CA: A Cancer Journal for Clinicians, vol. 62, no. 1, pp. 10–29, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Lee, C.-S. Wuu, R. Brody et al., “Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy,” International Journal of Radiation Oncology, Biology, Physics, vol. 48, no. 5, pp. 1457–1460, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Mallick, R. Azzouzi, L. Cormier, D. Peiffert, and P. Mangin, “Urinary morbidity after 125I brachytherapy of the prostate,” British Journal of Urology International, vol. 92, no. 6, pp. 555–558, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. J. A. Cesaretti, N. N. Stone, and R. G. Stock, “Urinary symptom flare following I-125 prostate brachytherapy,” International Journal of Radiation Oncology, Biology, Physics, vol. 56, no. 4, pp. 1085–1092, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. J. G. Blaivas, J. P. Weiss, and M. Jones, “The pathophysiology of lower urinary tract symptoms after brachytherapy for prostate cancer,” British Journal of Urology International, vol. 98, no. 6, pp. 1233–1237, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. H. K. Lee, M. T. Adams, Q. Shi et al., “Seed implant retention score predicts the risk of prolonged urinary retention after prostate brachytherapy,” International Journal of Radiation Oncology, Biology, Physics, vol. 76, no. 5, pp. 1445–1449, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. W. R. Lee, R. P. McQuellon, and D. L. McCullough, “A prospective analysis of patients reported quality of life after prostate brachytherapy,” Seminars in Urologic Oncology, vol. 18, no. 2, pp. 147–151, 2000. View at Google Scholar · View at Scopus
  8. G. S. Merrick, W. M. Butler, J. H. Lief, and A. T. Dorsey, “Temporal resolution of urinary morbidity following prostate brachytherapy,” International Journal of Radiation Oncology, Biology, Physics, vol. 47, no. 1, pp. 121–128, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. T. T. Wagner, S. Nag, D. Young, and R. R. Bahnson, “Early voiding dysfunction associated with prostate brachytherapy,” Urologic Oncology, vol. 6, no. 1, pp. 20–23, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. D. B. Bylund, D. C. Eikenberg, J. P. Hieble et al., “International union of pharmacology nomenclature of adrenoceptors,” Pharmacological Reviews, vol. 46, no. 2, pp. 121–136, 1994. View at Google Scholar · View at Scopus
  11. G. A. Michelotti, D. T. Price, and D. A. Schwinn, “α1-adrenergic receptor regulation: basic science and clinical implications,” Pharmacology & Therapeutics, vol. 88, no. 3, pp. 281–309, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Hampel, P. C. Dolber, M. P. Smith et al., “Modulation of bladder α1-adrenergic receptor subtype expression by bladder outlet obstruction,” The Journal of Urology, vol. 167, no. 3, pp. 1513–1521, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. M. S. Smith, U. B. Schambra, K. H. Wilson, S. O. Page, and D. A. Schwinn, “α1-Adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding α1-adrenergic receptor subtypes at four distinct levels,” Molecular Brain Research, vol. 63, no. 2, pp. 254–261, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. Q. Chen, S. Takahashi, S. Zhong et al., “Function of the lower urinary tract in mice lacking α1d- adrenoceptor,” The Journal of Urology, vol. 174, no. 1, pp. 370–374, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Shibata, R. Foglar, K. Horie et al., “KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues,” Molecular Pharmacology, vol. 48, no. 2, pp. 250–258, 1995. View at Google Scholar · View at Scopus
  16. R. Takei, I. Ikegaki, K. Shibata, G. Tsujimoto, and T. Asano, “Naftopidil, a novel α1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human α1-adrenoceptors,” The Japanese Journal of Pharmacology, vol. 79, no. 4, pp. 447–454, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Tatemichi, K. Kobayashi, A. Maezawa, M. Kobayashi, Y. Yamazaki, and N. Shibata, “α1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213),” Yakugaku Zasshi, vol. 126, pp. 209–216, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. J. C. Nickel, “The use of α1-adrenoceptor antagonists in lower urinary tract symptoms: beyond benign prostatic hyperplasia,” Urology, vol. 62, no. 3, supplement 1, pp. 34–41, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. G. S. Merrick, W. M. Butler, K. E. Wallner, Z. Allen, R. W. Galbreath, and J. H. Lief, “Brachytherapy-related dysuria,” British Journal of Urology International, vol. 95, no. 4, pp. 597–602, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. M. A. Elshaikh, J. C. Ulchaker, C. A. Reddy et al., “Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study,” International Journal of Radiation Oncology, Biology, Physics, vol. 62, no. 1, pp. 164–169, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Kobayashi, R. Tang, E. Shapiro, and H. Lepor, “Characterization and localization of prostatic alpha1 adrenoceptors using radioligand receptor binding on slide-mounted tissue section,” The Journal of Urology, vol. 150, no. 6, pp. 2002–2006, 1993. View at Google Scholar · View at Scopus
  22. H. Sakai, T. Igawa, T. Onita et al., “Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication,” Hinyokika Kiyo, vol. 57, no. 1, pp. 7–13, 2011. View at Google Scholar · View at Scopus
  23. N. Moriyama, S. Kurimoto, S. Horie et al., “Detection of of α1-adrenoceptor subtypes in human hypertrophied prostate by in situ hybridizationsubtypes in human hypertrophied prostate by in situ hybridization,” The Histochemical Journal, vol. 28, no. 4, pp. 283–288, 1996. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Nasu, N. Moriyama, K. Kawabe et al., “Quantification and distribution of α1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue,” British Journal of Pharmacology, vol. 119, no. 5, pp. 797–803, 1996. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Tsumura, T. Satoh, H. Ishiyama et al., “Comparison of prophylactic naftopidil, tamsulosin, and silodosin for 125I brachytherapy-induced lower urinary tract symptoms in patients with prostate cancer: randomized controlled trial,” International Journal of Radiation Oncology, Biology, Physics, vol. 81, no. 4, pp. e385–e392, 2011. View at Publisher · View at Google Scholar · View at Scopus